Get in touch today 206.598.4100 or

Schedule an Appointment

Christine Fang, M.D.

Assistant Professor

Locations of Practice

Overview

Dr. Fang is a radiation oncologist who specializes in treating breast and gynecologic cancers. She has special expertise in proton beam radiation therapy.

Patient Care Philosophy

The most important aspect to my work is delivering the best care possible to my patients. This includes evidence-based, personalized medical management, compassion, empathy, patience, and delivery of hope. I believe in treating the person, not the disease. I place a strong emphasis on clear communication with my patients so that there is a clear understanding of the disease process, prognosis, treatment options, and what is to be expected during treatment.

Education and Training

College: University of California at Berkeley, Berkeley, CA, 1999

Medical School: University of Utah School of Medicine, Salt Lake City, UT, 2005

Residency: University of Washington Medical Center, Seattle, WA, 2010

Fellowship: Proton Therapy, MD Anderson Cancer Center, Houston, TX, 2011

Selected Publications from a Total of 14:

Fagundes M, Hug E, Pankuch M, Fang LC, McNeeley S, Mao L, Lavilla M, Schmidt S, Ward C, Cahlon O, Hartsell W. Proton Therapy for Local-regionally Advanced Breast Cancer Maximizes Cardiac Sparing. International Journal of Particle Therapy. Spring 2015, Vol. 1, (4):827-844.

Laramore GE, Zeng J, Fang LM, Liao JJ, and Russell KJ (2015) Pathology Review for Patients with Prostate Cancer Referred to the SCCA Proton Center. International Journal of Particle Therapy. Spring 2015, Vol. 1, (4):878-883.

Chen LA, Anker CJ, Hunt JP, Buchmann LO, Grossmann KF, Boucher K, Fang LM, Shrieve DC, Hitchcock YJ. Clinical outcomes associated with evolving treatment modalities and radiation techniques for base-of-tongue carcinoma: thirty years of institutional experience. Cancer Med. 2015 May;4(5):651-60.

Javid SH, Fang LC, Korde L, Anderson BO. Renaming ductal carcinoma in situ: would removing “carcinoma” reduce overtreatment? J Natl Compr Canc Netw. 2014 Apr;12(4):599-602.

Fang LC, Merrick GS, Butler WM, Galbreath RW, Murray BC, Reed JL, Adamovich E, Wallner KE. High-risk prostate cancer with Gleason score 8-10 and PSA level ≤15 ng/mL treated with permanent interstitial brachytherapy. Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):992-6.

Lemos BD, Storer BE, Iyer JG, Phillips JL, Bichakjian CK, Fang LC, Johnson TM, Liegeois-Kwon NJ, Otley CC, Paulson KG, Ross MI, Yu SS, Zeitouni NC, Byrd DR, Sondak VK, Gershenwald JE, Sober AJ, Nghiem P. Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: analysis of 5823 cases as the basis of the first consensus staging system. J Am Acad Dermatol. 2010 Nov;63(5):751-61.

Fang LC, Merrick G, Wallner K. Androgen Deprivation Therapy—A Survival Benefit or Detriment in Men with High-Risk Prostate Cancer? Oncology 2010 Aug 24; 24(9):790-6, 798.

Fang LC, Lemos B, Douglas J, Iyer J, Nghiem P. Radiation monotherapy as regional treatment for lymph node-positive Merkel cell carcinoma. Cancer. 2010 Apr 1;116(7):1783-90

Fang LC, Dattoli M, Taira A, True L, Sorace R, Wallner K. Prostatic acid phosphatase adversely affects cause-specific survival in patients with intermediate to high-risk prostate cancer treated with brachytherapy. Urology. 2008 Jan;71(1):146-50.

Hitchcock YJ, Bentz BG, Sharma PK, Fang C, Tward JD, Pappas L, Chen J, Hayes JK, Shrieve DC. Planned neck dissection after definitive radiotherapy or chemoradiation for base of tongue cancers. Otolaryngol Head Neck Surg. 2007 Sep;137(3):422-7.

Research Interests

  • Genitourinary Cancer Treatments
  • Breast Cancer